Why tocilizumab could be an effective treatment for severe COVID-19?
Fu B, Xu X, Wei H. · 2020
Read Why tocilizumab could be an effective treatment for severe COVID-19? by Fu B, Xu X, Wei H. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7154566.txt.
Description
Fu, Xu, and Wei argue that tocilizumab, a drug that blocks the interleukin-6 pathway, could treat severe COVID-19, in the Journal of Translational Medicine. About 25% of patients developed severe complications such as acute respiratory distress syndrome. Autopsy samples suggested a runaway immune response and cytokine storm clog the air sacs and drive the high death rate.
Their earlier work found pathogenic T cells and inflammatory monocytes pouring out interleukin-6 in severe cases. Blocking its receptor with tocilizumab gave encouraging early clinical results: fevers settled quickly and breathing improved. The authors present the drug as a way to calm the inflammatory storm and cut deaths in the sickest patients.
Catalog record
| CREATOR | Fu B, Xu X, Wei H. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 15 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |